 |
|
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways
Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim
Clin Mol Hepatol. 2022;28(4):827-840. Published online 2022 Jun 22 DOI: https://doi.org/10.3350/cmh.2022.0068
|
|
Citations to this article as recorded by
 Activation of AMPK pathway by low‑dose donafenib and atorvastatin combination improves high‑fat diet‑induced metabolic dysfunction‑associated steatotic liver disease
Yaowei Bai, Kequan Chen, Jiacheng Liu, Yingliang Wang, Chaoyang Wang, Shuguang Ju, Chen Zhou, Wei Yao, Bin Xiong, Chuansheng Zheng
Molecular Medicine Reports.2024;[Epub] CrossRef Network pharmacology and transcriptomic profiling elucidate the therapeutic effects of Ranunculus ternatus Thunb on liver fibrosis via MK3-NF-κB inhibition
Lu Han, Guoyuan Lin, Jianchao Li, Qingxiu Zhang, Tao Ran, Tao Huang, Ruihan Hu, Shu Feng, Gaoliang Zou, Shaojie Chen, Xueke Zhao
Aging.2024;[Epub] CrossRef Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018
Daniela P. Ladner, Michael Gmeiner, Bima J. Hasjim, Nikhilesh Mazumder, Raymond Kang, Emily Parker, John Stephen, Praneet Polineni, Anna Chorniy, Lihui Zhao, Lisa B. VanWagner, Ronald T. Ackermann, Charles F. Manski, Sona Frankova
PLOS ONE.2024; 19(2): e0298887. CrossRef Oxysophoridine Inhibits Oxidative Stress and Inflammation in Hepatic Fibrosis via Regulating Nrf2 and NF-κB pathways
Jian-Yu Chen, Ying-Jie Yang, Xiong-Yu Meng, Ru-Hui Lin, Xiao-Yun Tian, Ying Zhang, Wen-Fang Lai, Chunxue Yang, Xue-Qin Ma, Ming-Qing Huang
Phytomedicine.2024; : 155585. CrossRef NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies
Aryan Rezaee, Parham Rahmanian, Amirreza Nemati, Farima Sohrabifard, Fatemeh Karimi, Ali Elahinia, Ali Ranjbarpazuki, Rozhin Lashkarbolouki, Sadaf Dezfulian, Mohammad Arad Zandieh, Shokooh Salimimoghadam, Noushin Nabavi, Mohsen Rashidi, Afshin Taheriazam,
Heliyon.2024; : e29871. CrossRef Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Yuanbin Liu, Mingkai Chen
Clinical and Molecular Hepatology.2023; 29(1): 163. CrossRef Oleoylethanolamide alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPARα
Zhengdong Chen, Xuejiao Sun, Xiaoxue Li, Naifeng Liu
Biochemical Pharmacology.2023; 208: 115379. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease
James Li, Sandra Arest, Bartlomiej Olszowy, John Gordon, Carlos A. Barrero, Oscar Perez-Leal
Antioxidants.2023; 12(7): 1363. CrossRef Perfluorodecanoic acid promotes high-fat diet-triggered adiposity and hepatic lipid accumulation by modulating the NLRP3/caspase-1 pathway in male C57BL/6J mice
Taotao Wang, Hong Xu, Yu Guo, Yuanxin Guo, Huanan Guan, Dongxu Wang
Food and Chemical Toxicology.2023; 178: 113943. CrossRef Higher pNRF2, SOCS3, IRF3, and RIG1 Tissue Protein Expression in NASH Patients versus NAFL Patients: pNRF2 Expression Is Concomitantly Associated with Elevated Fasting Glucose Levels
Suzan Schwertheim, Malek Alhardan, Paul P. Manka, Jan-Peter Sowa, Ali Canbay, Hartmut H.-J. Schmidt, Hideo A. Baba, Julia Kälsch
Journal of Personalized Medicine.2023; 13(7): 1152. CrossRef Molecular mechanisms and clinical implications of the gold drug auranofin
Shuying Shen, Jie Shen, Zhong Luo, Fudi Wang, Junxia Min
Coordination Chemistry Reviews.2023; 493: 215323. CrossRef Impaired NRF2 Inhibits Recovery from Ischemic Reperfusion Injury in the Aging Kidney
Min Jee Jo, Ji Eun Kim, So Yon Bae, Eunjung Cho, Shin Young Ahn, Young Joo Kwon, Gang-Jee Ko
Antioxidants.2023; 12(7): 1440. CrossRef Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
Kuanhong Luo, Yang Chen, Shuzheng Fang, Siqi Wang, Zhixin Wu, Huiqing Li
Frontiers in Endocrinology.2023;[Epub] CrossRef Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE
Layla A. Al-Kharashi, Naif O. Al-Harbi, Sheikh F. Ahmad, Sabry M. Attia, Mohammad M. Algahtani, Khalid E. Ibrahim, Saleh A. Bakheet, Mohammed M. Alanazi, Saleh A. Alqarni, Sary Alsanea, Ahmed Nadeem
Biomedicines.2023; 11(9): 2502. CrossRef TrxR/Trx inhibitor butaselen ameliorates pulmonary fibrosis by suppressing NF-κB/TGF-β1/Smads signaling
Yifan Chen, Hanwei Yin, Jing Sun, Guozhou Zhang, Ying Zhang, Huihui Zeng
Biomedicine & Pharmacotherapy.2023; 169: 115822. CrossRef Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
Carlos J. Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2022; 28(4): 806. CrossRef
|